Shanghai's National Center for Biochip Technology Purchases Production-Scale SNP Genotyping BeadLab from Illumina.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--June 30, 2003 Illumina's BeadArray(TM) Technology Will Be Key Platform for China's Growing Contribution to the Understanding of Genetic Variation and Function Illumina, Inc. (Nasdaq: ILMN) announced today an agreement with the National Center for Biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of Technology (NCBT NCBT National College of Business and Technology NCBT North Carolina Birding Trail NCBT Newell Collections of Babylonian Tablets ) in Shanghai, China for the purchase of Illumina's BeadLab, a production-scale SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily (single nucleotide polymorphism Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a ) genotyping laboratory. Illumina's laboratory solution will constitute an integral component of NCBT's extensive resources devoted to understanding the functional implications of SNP-based sequence variation in the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. and other model organisms. The BeadLab will be installed in the new NCBT facility in Shanghai and used by the Center for large-scale genotyping projects such as the identification of genes associated with complex disease and the stratification of patient populations based on genetic differences to enable better therapeutic outcomes. The BeadLab will also help support research related to China's participation in the International HapMap Project The International HapMap Project is an organization whose goal is to develop a haplotype map of the human genome (the HapMap), which will describe the common patterns of human genetic variation. . The genotyping laboratory solution is built around Illumina's proprietary BeadArray(TM) technology and features high sample throughput, unprecedented multiplex levels, LIMS LIMS Laboratory Information Management System LIMS Library Information Management System LIMS Limb Infrared Monitor of the Stratosphere LIMS Land Information Management System (Canada) LIMS Logistics Information Management System (laboratory information management system) control and low running cost per SNP scored. The complete offering is fully integrated to ensure optimal SNP genotyping performance. Included in the turnkey offering are the BeadArray Reader, GoldenGate(TM) assay protocols, LIMS and analytical software, fluid-handling robotics, and access to Sentrix(TM) array matrices and reagent supply, along with installation, start-up, training, and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services . According to Jay Flatley, Illumina President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , "We're very pleased to begin working with NCBT and to support the efforts of co-directors Dr. Guoping Zhao and Dr. Hongjun (Harry) Yang and their team in creating a world-class genomics research facility. Thanks to the anticipated contributions of NCBT and related organizations in high-throughput genotyping, we expect that China will quickly grow to become a global leader in the understanding of genetic variation and function." "We're pleased to introduce Illumina's genotyping system into Shanghai, China. It's not only speeding up our course to establish a modern genomic research center, but also will make significant contributions to our participation in the international HapMap project. We are looking forward to long term collaboration with Illumina," Dr. Yang said. The National Center for Biochip Technology, Shanghai/Shanghai Biochip Co, Ltd. (www.shbiochip.com) was founded in August, 2001. The firm focuses on biotechnology research and development and has close working relationships with China's National Human Genome Centers in Shanghai and Beijing and with the Chinese Academy of Sciences The Chinese Academy of Sciences (CAS) (Simplified Chinese: 中国科学院; Pinyin: Zhōngguó Kēxuéyuàn), formerly known as Academia Sinica . Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements are Illumina's ability to fully develop its BeadArray and Oligator technologies, the Company's ability to successfully build international sales and support organizations to install and service its laboratory facilities at customer locations, the Company's ability to develop and deploy new applications for its platform technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion